Related Experiment Videos
Treatment of hypertension in patients 80 years of age or older
M F O'rourke1, M Namasivayam, A Adji
1St Vincent's Clinic, University of New South Wales, Sydney, Australia. m.orourke@unsw.edu.au
Insights
Isolated systolic hypertension (ISH) affects most individuals over 80 due to arterial stiffening. Recent studies like HYVET support treating ISH in this age group, aligning with SHEP guidelines.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Clinical Pharmacology
Background:
- Isolated systolic hypertension (ISH) is prevalent in individuals aged 80 and above.
- Arterial stiffening of the aorta and large elastic arteries is a primary cause of ISH.
- Treatment consensus for ISH in the very elderly was lacking before recent trials.
Purpose of the Study:
- To review the background of the Systolic Hypertension in the Elderly Project (SHEP) and Hypertension in the Very Elderly Trial (HYVET) studies.
- To explain the impact of aging on arterial stiffness and its consequences.
- To discuss the rationale for antihypertensive therapy in older adults and propose treatment strategies.
Main Methods:
- Review of existing literature and clinical trial data (SHEP, HYVET).
- Analysis of physiological changes related to aging and hypertension.
- Evaluation of antihypertensive mechanisms and their efficacy in the elderly.
Main Results:
- The HYVET study supports applying SHEP treatment principles to most individuals over 80 with ISH.
- Arterial stiffness significantly affects cardiovascular, cerebral, and renal health in the elderly.
- Newer antihypertensives offer a basis for treating ISH by indirectly addressing arterial stiffness.
Conclusions:
- Antihypertensive therapy is recommended for most individuals over 80 with ISH, based on HYVET findings.
- Understanding arterial stiffness is crucial for managing hypertension in the very elderly.
- Evidence-based strategies for initiating and managing antihypertensive treatment in individuals over 80 are proposed.
Abstract:
Isolated systolic hypertension (ISH) is present in the majority of persons who reach the age of 80 years, and is caused directly or indirectly by stiffening of the aorta and large central elastic arteries. Until recently, there was no consensus on whether or not persons over 80 should be treated, according to principles established for the younger group examined in the Systolic Hypertension in the Elderly Project (SHEP). The recent Hypertension in the Very Elderly Trial (HYVET) study endorses application of SHEP to most such subjects. This review describes the background to SHEP and HYVET, including concepts of hypertension and interpretation of blood pressure values. It describes the effects of age on arterial stiffness, and effects of stiffness on the heart, large arteries and microvessels in brain and kidneys as the basis of symptomatic disease. It describes logic of therapy with newer antihypertensives which indirectly affect arterial stiffness and form the basis of therapy in older persons. It proposes how, with what and in whom antihypertensive therapy could be offered in persons over age 80.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management
Hypertension I: Introduction
Drug Dosing: Geriatric Patients
Hypertension and Regulation of Blood Pressure
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution